Top Marijuana Stocks to Watch in 2026: A Practical Overview
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always consult a licensed financial advisor before making investment decisions.
Why marijuana stocks are back on investor radar
Marijuana stocks are publicly traded shares in companies that grow, process, distribute, or sell cannabis products. The sector took a beating after the initial hype cycle of 2018-2021, but 2026 has brought renewed interest. More U.S. states continue legalizing cannabis for medical and recreational use, and the possibility of federal rescheduling under Schedule III has given the industry a second wind.
The companies below have survived the shakeout period and emerged with stronger balance sheets, positive cash flow, and expanding retail footprints. Here is what each one brings to the table.
Top marijuana stocks to watch
Green Thumb Industries (GTBIF)
Green Thumb Industries is a Chicago-based cannabis company that cultivates and sells marijuana for both medical and recreational use. The company operates more than 90 retail locations across 15 U.S. states under the RISE dispensary brand.
Green Thumb has been one of the few cannabis operators to report consistent profitability. Revenue for fiscal year 2025 came in at approximately $1.1 billion, according to Investopedia’s cannabis sector tracker. The company generates positive free cash flow and has managed its debt load better than most peers in the space.
Trulieve Cannabis (TCNNF)
Trulieve Cannabis dominates the Florida medical marijuana market, holding roughly 30% market share in the state. The company runs over 190 dispensaries across the U.S., with heavy concentration in Florida, Pennsylvania, and Arizona.
Trulieve reported $1.2 billion in annual revenue for 2025. What makes Trulieve interesting for investors is its position in Florida, where adult-use legalization could unlock a massive new revenue stream. The company also controls much of its supply chain, from cultivation to retail, which keeps margins tighter than competitors who rely on third-party suppliers.
Cronos Group (CRON)
Cronos Group is a Toronto-based cannabis holding company with investments in medical marijuana producers like Peace Naturals. The company sells medical cannabis under the Peace Naturals brand and recreational products under the Spinach and Cove brands. It also offers CBD products through the Lord Jones and Peace+ labels.
Cronos trades on the NASDAQ, which gives it more visibility with institutional investors compared to OTC-listed competitors. The company has been slower to scale than peers but carries less debt as a result. Revenue for 2025 was approximately $95 million, with the bulk coming from Canadian retail channels.
Canopy Growth Corporation (CGC)
Canopy Growth is one of the oldest publicly traded cannabis companies, operating since 2013 out of Smiths Falls, Ontario. The company received a major capital injection in 2017 when Constellation Brands, the parent company behind Corona and Modelo, acquired a 9.9% stake.
Canopy owns the Tweed brand, one of the most recognized names in Canadian recreational marijuana. The company has struggled with profitability in recent years but has been aggressively cutting costs and restructuring operations. Bank of America analysts maintain a buy rating based on potential U.S. market entry and federal legalization tailwinds.
GW Pharmaceuticals (now Jazz Pharmaceuticals)
GW Pharmaceuticals, acquired by Jazz Pharmaceuticals in 2021, developed Epidiolex, the only FDA-approved cannabis-derived medication in the United States. Epidiolex treats seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome, two severe forms of epilepsy.
Epidiolex generated over $900 million in global sales during 2025, with the U.S. market accounting for roughly 80% of that figure. The drug has also received approval in multiple European markets including Germany, France, and the UK. Jazz Pharmaceuticals continues pursuing additional indications for Epidiolex, including tuberous sclerosis complex.
Comparing the top marijuana stocks
| Company | Ticker | Headquarters | 2025 Revenue (approx.) | Key strength |
|---|---|---|---|---|
| Green Thumb Industries | GTBIF | Chicago, IL | $1.1 billion | Consistent profitability |
| Trulieve Cannabis | TCNNF | Quincy, FL | $1.2 billion | Florida market dominance |
| Cronos Group | CRON | Toronto, ON | $95 million | NASDAQ listing, low debt |
| Canopy Growth | CGC | Smiths Falls, ON | $280 million | Brand recognition, Constellation backing |
| Jazz Pharmaceuticals (GW) | JAZZ | Dublin, Ireland | $900 million (Epidiolex) | Only FDA-approved cannabis drug |
What could move marijuana stocks in 2026
Three factors will likely shape how marijuana stocks perform through the rest of 2026.
- Federal rescheduling. Moving cannabis from Schedule I to Schedule III would repeal the 280E tax provision. This single change could save the cannabis industry more than $3 billion annually by letting operators deduct ordinary business expenses like rent, payroll, and marketing.
- State-level legalization. New York’s retail dispensary rollout is gaining speed after years of delays. Florida, Pennsylvania, and Virginia could introduce adult-use legalization measures before the end of 2026, opening large new consumer markets.
- Uplisting to major exchanges. U.S. cannabis companies currently trade on OTC markets because federal prohibition prevents NYSE and NASDAQ listings. Rescheduling could change that, bringing higher trading volumes and institutional investor access.
Risks to keep in mind
Cannabis remains a volatile sector. Federal legalization timelines have slipped repeatedly, and regulatory progress can reverse with changes in political leadership. Many cannabis companies carry significant debt from the rapid expansion era of 2018-2020. Price competition in mature markets like Colorado and Oregon has compressed margins, and new state markets often take longer to generate revenue than projections suggest.
Liquidity is another concern. OTC-listed marijuana stocks tend to have lower trading volumes than exchange-listed equities, which means wider bid-ask spreads and sharper price swings on news events.
Frequently asked questions
Will marijuana stocks recover in 2026?
Analysts see cautious optimism for marijuana stocks in 2026. After years of decline, the industry may be reaching a turning point thanks to stronger company balance sheets and growing regulatory momentum at the federal level.
How does the Schedule III rescheduling delay affect marijuana stocks?
Rescheduling cannabis to Schedule III would automatically repeal the 280E tax provision, which currently prevents cannabis companies from deducting standard business expenses like rent and wages. Industry estimates suggest this could save the sector over $3 billion in 2026.
Are cannabis companies profitable in 2026?
Several major operators have shifted from growth-at-all-costs to profitability. Green Thumb Industries and Tilray Brands both report positive net income or consistent positive cash flow, marking a real change in how the industry operates.
Why are marijuana stocks so volatile?
Cannabis stock prices react sharply to federal policy signals and legislative announcements. Many U.S. operators trade on over-the-counter (OTC) markets rather than major exchanges like the NYSE or NASDAQ, which means lower trading volume and more pronounced price swings.
Which U.S. states will drive the most cannabis market growth?
New York is widely seen as a growth driver as retail dispensary rollouts accelerate. Florida, Pennsylvania, and Virginia are also on investor watchlists for potential adult-use legalization measures expected in late 2026.
